

State of Oklahoma SoonerCare



Venclexta® (venetoclax) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	າ
Pharmacy Billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Pharmacy Informat	tion
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Cri		
2. Will venetoclax be used as first 3. Will venetoclax be used as set 4. Will venetoclax be used for ret 5. Please indicate the diagnosis Chronic Lymphocytic A. Will venetoclas B. Will venetoclas C. Will venetoclas C. Will venetoclas Acute Myeloid Leuke A. Will venetoclas Yes No B. Is member you Yes No Mantle Cell Lymphor	c Leukemia (CLL)/Small Lymphoc x be used in combination with obinut x be used in combination with ibrutin x be used in combination with rituxin emia (AML) x be used in combination with azacit unger than 75 years of age and unal	eytic Lympoma (SLL) tuzumab? Yes No
	ence of progressive disease while on any adverse drug reactions related actions:	
Prescriber Signature:		Date:
		ion is true and correct to the best of my knowledge.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

processing delays.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm-102 5/6/2025